Azitra, Inc. AZTR
Azitra, Inc. was formed as a Delaware corporation on January 2, 2014 as a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Since our formation, we have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. We have not commenced commercial operations. Unless otherwise indicated, the terms "Azitra," Company," "we," "us," and "our" refer to Azitra, Inc. and its wholly-owned subsidiaries.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $7.5K | $686.0K | $284.0K | — |
| R&D | $4.8M | $4.7M | $3.6M | $6.1M | — |
| SG&A | $6.1M | $6.3M | $4.5M | $3.6M | — |
| Total operating expenses | $11.0M | $11.0M | $8.1M | $9.7M | — |
| Operating income | -$11.0M | -$11.0M | -$7.5M | -$9.5M | — |
| Interest expense | $7.6K | $12.2K | $167.7K | $251.9K | — |
| Pre-tax income | -$10.9M | -$9.0M | -$11.3M | -$10.7M | — |
| Income tax | $8.3K | $9.0K | $17.3K | — | — |
| Net income | -$11.0M | -$9.0M | -$11.3M | -$10.7M | — |
| EPS, basic | -2.25 | -15.70 | -54.98 | -12.74 | — |
| EPS, diluted | -2.25 | -15.70 | -54.98 | -12.74 | — |
| Shares, diluted (wtd. avg.) | $4.9M | $571.2K | $229.9K | $1.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $2.1M | $4.6M | $1.8M | $3.5M | $8.0M |
| Receivables | $912 | $233 | — | $175.0K | — |
| Total current assets | $3.0M | $5.2M | $2.5M | $4.1M | — |
| Property, plant and equipment | $548.6K | $654.0K | $710.1K | $847.0K | — |
| Other intangibles | $316.7K | $246.4K | $210.9K | $219.6K | — |
| Total assets | $5.0M | $7.4M | $5.1M | $7.2M | — |
| Accounts payable | $399.4K | $490.3K | $897.3K | $784.7K | — |
| Total current liabilities | $1.1M | $1.4M | $1.6M | $2.2M | — |
| Total liabilities | $1.2M | $1.7M | $2.2M | $9.7M | — |
| Retained earnings | -$68.5M | -$57.6M | -$48.6M | -$37.3M | — |
| Total equity | $2.2M | $5.7M | $2.9M | -$36.3M | -$25.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$11.2M | -$10.2M | -$7.4M | -$8.3M | — |
| Depreciation and amortisation | $138.1K | $131.2K | $129.7K | $125.9K | — |
| Stock-based compensation | $62.7K | $245.1K | $151.5K | $184.5K | — |
| Capital expenditure | $24.2K | $8.6K | $26.5K | $33.1K | — |
| Investing cash flow | -$182.9K | -$379.2K | -$318.3K | -$336.8K | — |
| Financing cash flow | $8.9M | $13.3M | $6.0M | $4.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001701478-26-000013.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |